A practical reference on c-Met signaling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Co-Founder, Beacon Collaborative and Director, Rosa Fund. For services to Philanthropy, to Women and Girls, to the Arts and to the Economy. Charles Henry, Duke of Richmond and Gordon, DL. For services to Heritage, to Sport and to Charity. Kevin James David Ellis. Alliance Senior Partner, PwC UK and Middle East. For services to Economic Growth and Expanding Social Mobility. Nicholas Emery. Founding Partner and Chief Executive Officer, Brandtech Media. For services to the Media and Marketing Industries. Professor Paul Emery, OBE. Versus Arthritis Professor of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds. For services to Rheumatology. Professor Penelope Claire Endersby, FREng. Chief Executive Officer, Met Office. For services to Meteorology, to Defence Science and to Technology. Professor Kenneth John Falconer, FRSE. Regius Professor of Mathematics, University of St Andrews. For services to Mathematics. Angela Foulkes. Chief Executive and Principal, The Sheffield College. For services to Further Education. Yvonne Helen Fovargue, MP. Member of Parliament for Makerfield. For Political and Public Service. Timothy David Gardam. Journalist. For services to Journalism and to Education. Professor Danielle Amanda George, MBE. Professor of Radio Frequency Engineering, University of Manchester. For services to Public Engagement in Engineering. Dr. Phillip Anthony George. Lately Chair, Arts Council of Wales. For services to the Arts in Wales. Paul William Martin Golding. Chair, Pinewood Group.
"Candidatus Magnetoglobus multicellularis" is a species of multicellular magnetotactic bacteria (MMB). Samples of "Ca. M. multicellularis" were first collected at the Araruama Lagoon in Rio de Janeiro, Brazil. It has a multicellular structure and consists of an organised sphere of flagellated, gram-negative bacterial cells. As it has not yet been cultured under laboratory conditions, it retains the title Candidatus.
==== Russia ==== According to the Foreign Policy Research Institute, Russia has 112 think tanks, while Russian think tanks claimed four of the top ten spots in 2011's "Top Thirty Think Tanks in Central and Eastern Europe". Notable Russian think tanks include:
Sources: en.wikipedia.org
AGPs belong to large multigene families and are divided into several sub-groups depending on the predicted protein sequence. "Classical" AGPs include the GPI-AGPs that consist of a signal peptide at the N-terminus, a PAST-rich sequence of 100-150 aa and a hydrophobic region at the C-terminus that directs addition of a GPI-anchor; non GPI-AGPs that lack the C-terminal GPI signal sequence, Lysine(K)-rich AGPs that contain a K-rich region within the PAST-rich backbone and AG-peptide that have a short PAST-rich backbone of 10-15 aa (Figure 2). Chimeric AGPs consist of proteins that have an AGP region and an additional region with a recognised protein family (Pfam) domain. Chimeric AGPs include fasciclin-like AGPs (FLAs), phytocyanin-like AGPs (PAGs/PLAs, also known as early-nodulin-like proteins, ENODLs) and xylogen-like AGPs (XYLPs) that contain lipid-transfer-like domains. Several other putative chimeric AGP classes have been identified that include AG glycomotifs associated with protein kinase, leucine-rich repeat, X8, FH2 and other protein family domains. Other non-classical AGPs exist such as those containing a cysteine(C)-rich domain, also called PAC domains, and/or histidine(H)-rich domain, as well as many hybrid HRGPs that have motifs characteristic of AGPs and other HRGP members, usually extensin and Tyr motifs. AGPs are evolutionarily ancient and have been identified in green algae as well as Chromista and Glaucophyta.
Presidential elections were held in the United States on November 5, 2024. The Republican ticket of former president Donald Trump and Ohio junior senator JD Vance defeated the Democratic ticket of incumbent vice president Kamala Harris and Minnesota governor Tim Walz. The incumbent president, Joe Biden of the Democratic Party, initially ran for re-election, easily sweeping aside a challenge from Democratic representative Dean Phillips of Minnesota in the Democratic primaries to become the party's presumptive nominee. However, what was broadly considered a poor debate performance in June 2024 intensified concerns about his age and health, and led to calls within his party for him to leave the race. After initially declining to do so, Biden ultimately withdrew from the race on July 21, 2024, becoming the first eligible incumbent president to run but subsequently withdraw since Lyndon B. Johnson in 1968. Biden immediately endorsed Harris, who officially became the party's presidential nominee on August 5 and the first presidential nominee who did not participate in the primaries since Vice President Hubert Humphrey in 1968. Harris selected Walz as her running mate. Trump, who lost the 2020 presidential election to Biden, ran for reelection to a nonconsecutive second term. Trump became the presumptive Republican Party's presidential nominee on March 12, 2024, easily defeating challengers such as former South Carolina governor Nikki Haley and Florida governor Ron DeSantis in the Republican primaries. He was shot in the ear in an assassination attempt on July 13, 2024.
=== Bas–Ben === Fred Basolo (1920–2007), American chemist known for the mechanisms of inorganic reactions Esther Batchelder (1897–1987), American chemist, educator and specialist in nutrition Sir Alan Battersby (1925–2018), English organic chemist known for work on biosynthetic pathways Antoine Baumé (1728–1804), French chemist, inventor of the Baumé scale hydrometer for measuring the density of liquids Karl Bayer (1847–1904), Austrian chemist who invented the Bayer process of extracting alumina from bauxite Johann Joachim Becher (1635–1682), German who developed the phlogiston theory of combustion Friedrich Konrad Beilstein (1838–1906), German-Russian chemist, created Beilstein database Joseph Achille Le Bel (1847–1930), French chemist, early work in stereochemistry addressing the relationship between molecular structure and optical activity Angela Belcher (PhD 1997), American chemist, materials scientist, and biological engineer Irina Beletskaya (born 1933), Russian organometallic chemist known for studies on aromatic reaction mechanisms R. P. (Ronnie) Bell (1907–1996), English physical chemist known in particular for The Proton in Chemistry Andrey Belozersky (1905–1972), Soviet biologist and biochemist, pioneer of molecular biology and the chemistry of nucelic acids Ruth R. Benerito (1916–2013), American chemist known for inventions relating to textiles, including wash-and-wear cotton fabrics
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.